Long-term Beta-blocker Therapy After Acute Myocardial Infarction

Summary

Participation Requirements

Description

?-blockers have anti-ischemic, anti-arrhythmic, and anti-adrenergic properties. In order to reduce cardiovascular mortality and morbidity, current major guidelines recommend that oral treatment of ?-blockers should be continued during and after hospitalization in patients with acute myocardial infar...

?-blockers have anti-ischemic, anti-arrhythmic, and anti-adrenergic properties. In order to reduce cardiovascular mortality and morbidity, current major guidelines recommend that oral treatment of ?-blockers should be continued during and after hospitalization in patients with acute myocardial infarction (AMI) and without contraindications to ?-blocker use. A clinically important but difficult decision on ?-blocker therapy after AMI is to determine the duration of ?-blocker therapy after discharge in patients without heart failure (HF) or left ventricular systolic dysfunction. Previous studies for long-term ?-blocker therapy after AMI were inadequate to derive definite conclusion because of small sample size and potential selection bias. Therefore, the SMART-DECISION trial will investigate whether discontinuation of ?-blocker after at least 1 year of ?-blocker therapy is noninferior to continuation of ?-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

Tracking Information